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Background: Novel multiplex assays allow the simultaneous identification of a large number of plasma proteins. While these new technologies have been shown to be highly sensitive and accurate for the identification of plasma proteins, the use of this technology to quantify those proteins has not been properly investigated. In this pilot study, we tested the accuracy of the proximity extension assay (PEA) for the quantification of the cardiac biomarker brain natriuretic peptide (BNP) compared to a standard clinically approved method.
Methods:
Concentrations of BNP were assessed in 120 plasma samples from 30 patients with PEA and compared to chemiluminescent microparticle immunoassay (CMIA). Venous blood samples were collected from in tubes containing ethylenediaminetetraacetic acid, centrifuged within 6 hours at 3,500 rpm for 15 minutes at 4°C, frozen and stored at −80°C until analyzed. Correlation between the CMIA and PEA techniques was tested using the Spearman's rank correlation coefficient (rho) and the agreement was described with a Bland-Altman plot.
Results:
Brain natriuretic peptide values obtained by CMIA and PEA were highly correlated (Spearman's rho = 0.865, P < .0001). In two patients, PEA consistently overestimated resp. underestimated BNP values compared to CMIA. After removal of those two patients, a very high correlation between the two techniques was shown (rho = 0.966, P < .0001). A high agreement between the two techniques over the whole range of tested concentrations was shown.
Conclusion:
This pilot study showed for the first time an excellent correlation between a clinically approved method and the PEA-based approach for quantification of circulating plasma BNP.
K E Y W O R D S
BNP, multiplex assay, natriuretic peptide, proteomics, proximity extension assay simultaneous measurement of >90 proteins using only one microliter of plasma. 2 The implementation of this technology might be particularly compelling for clinical or research purposes in populations with relevant comorbidities (eg, heart failure, end-stage renal disease), to test the concomitant activation of multiple pathways.
While these new technologies have been shown to be highly sensitive and accurate for the identification of plasma proteins, the use of this technology to quantify those proteins has not been properly investigated.
In this pilot study, we tested the accuracy of PEA for the quantification of the brain natriuretic peptide (BNP) in a cohort of chronic hemodialysis patients compared to a standard clinically approved method.
| MATERIAL S AND ME THODS
The study was performed from October 1st to December 31st, 2016
at the University Hospital of Zurich, Switzerland according to the standards of the Declaration of Helsinki and approved by the local ethics committee of Zurich. All patients provided written informed consent (ClinicalTrials.gov NCT02962635 
| RESULTS
Baseline characteristics of the study population were published elsewhere. 3 Briefly, the study population consisted of chronic stable showed a progressive loss of correlation with CMIA at around 500 pg/mL. 4 Furthermore, the fact that eight samples belonging to two patients did not fit with the correlation suggests pre-analytical anomalies in these samples that either interfere with CMIA or PEA 
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